AbbVie
ABBV
A$292.43
Share price
-0.48%
Change (1 day)
17.86%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
AbbVie (ABBV) - Cash on Hand
Cash on Hand as of March 2025 : A$7.90 Billion
According to AbbVie's latest financial reports the company has A$7.90 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
AbbVie - Cash on Hand chart (from 2011 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | A$8.93 B | -52.52% |
| 2023-12-31 | A$18.81 B | 38.7% |
| 2022-12-31 | A$13.56 B | 0.02% |
| 2021-12-31 | A$13.55 B | 22.96% |
| 2020-12-31 | A$11.02 B | -80.66% |
| 2019-12-31 | A$57.02 B | 398.34% |
| 2018-12-31 | A$11.44 B | -8.74% |
| 2017-12-31 | A$12.53 B | 40.72% |
| 2016-12-31 | A$8.91 B | -22.79% |
| 2015-12-31 | A$11.54 B | 12.78% |
| 2014-12-31 | A$10.23 B | -7.76% |
| 2013-12-31 | A$11.09 B | 44.54% |
| 2012-12-31 | A$7.67 B | 1105.16% |
| 2011-12-31 | A$0.63 B | 5903.75% |
| 2010-12-31 | A$10.6 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | A$26.43 B | 234.54% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | A$17.99 B | 127.63% | 🇺🇸 USA |
 Eli Lilly LLY | A$4.91 B | -37.78% | 🇺🇸 USA |
 Amgen AMGN | A$13.45 B | 70.21% | 🇺🇸 USA |
 Gilead Sciences GILD | A$12.10 B | 53.13% | 🇺🇸 USA |
 Biogen BIIB | A$3.96 B | -49.80% | 🇺🇸 USA |
 GlaxoSmithKline GSK | A$8.84 B | 11.96% | 🇬🇧 UK |
 AstraZeneca AZN | A$8.23 B | 4.23% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | A$1.44 B | -81.77% | 🇺🇸 USA |